{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-410663","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2026-10-01T20:08:04+00:00","discovered_at":"2026-10-01T20:09:00.734371+00:00","generated_at":"2026-10-12T14:22:22.775192+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Perspective Therapeutics (CATX) files updated corporate presentation covering four 212Pb radiopharmaceutical programs","bullets":["Perspective Therapeutics filed an updated corporate presentation (Exhibit 99.1) dated October 1, 2026, signed by CFO Joel Sendek.","Presentation cites a combined $45B+ addressable solid tumor market for VMT-α-NET, VMT01, PSV359 and PSV594.","VMT-α-NET Phase 1/2a data in SSTR2+ neuroendocrine tumors targeted for ASCO 2026; safety data shown for 68 treated patients.","VMT01 preliminary anti-tumor activity observed at the 3.0 mCi dose in melanoma; PSV359 shows improved tumor retention against FAP-α.","CCK2R81 is highlighted as a potential first-in-class agent in medullary thyroid cancer and selected solid tumors."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-410663","json":"https://secwatch.observer/filing/0001193125-26-410663.json","markdown":"https://secwatch.observer/filing/0001193125-26-410663.md","text":"https://secwatch.observer/filing/0001193125-26-410663.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000119312526410663/0001193125-26-410663-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000119312526410663/catx-20261001.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T14:22:22.775192+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}